Description
Semalgid 4 mg New Generation Pharma — semaglutide from New Generation Pharma at 4 mg. Weekly GLP-1 receptor agonist. Drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin release.
Key Benefits
- Serotonin-norepinephrine reuptake inhibitor — centrally-acting appetite suppressor
- Metabolic rate elevation modest; mechanism primarily satiety
- Withdrawn from many markets due to cardiovascular signal
- Oral daily dosing during cutting
- Not first-line in modern weight-loss protocols (GLP-1 agonists preferred)
- Each unit dosed at 4 mg — see Recommended Dosage below for protocol-specific intake
How It Works
Central serotonin and norepinephrine reuptake inhibitor (SNRI). Increases satiety signals and modestly raises basal metabolic rate. Withdrawn from EU, US, and most developed markets in 2010 after cardiovascular-event signal in SCOUT trial.
Pharmacokinetics
Plasma half-life approximately 14–16 hours (active metabolites longer). Daily morning dosing. Steady-state 4–5 days.
Potential Side Effects
Blood-pressure elevation, tachycardia, dry mouth, insomnia. Cardiovascular events in susceptible individuals — primary reason for market withdrawal. Not for hypertensive or CVD patients.
Cycle & Stacking Guide
8–12 week cutting protocols with weekly BP monitoring. Modern alternative: semaglutide or tirzepatide with far cleaner safety profile.
Manufacturer Notes
New Generation Pharma produces GLP-1 agonists and metabolic compounds. Cold-chain shipping for peptide products.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.